EGFR and non-small cell lung carcinoma: Like the latest reported AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with brain metastases [57], Lycorine may be developed clinically, with the goal of achieving high enough drug concentrations within the CNS.